The competitive landscape for US Antimony has shifted dramatically with the arrival of a formidable new rival. Korea Zinc’s entry into the U.S. market, significantly bolstered by a 40% investment stake from the Department of Defense, is reshaping the domestic supply chain for strategic materials. This development raises critical questions about the smaller producer’s ability to maintain its existing contracts and market position in the years leading up to the new facility’s operational launch.
Financial Performance Amidst Strategic Shifts
The company is confronting this new competition during a period of significant revenue growth that has yet to translate into profitability. Key figures from its most recent quarterly report illustrate this dynamic:
- Third-quarter sales surged by 238% to $8.7 million.
- The net loss expanded considerably to $4.8 million, compared to $729,000 in the prior-year period.
- Management has refined its 2025 revenue forecast to a range of $40–43 million, while maintaining a 2026 target of $125 million.
- Previous attempts at expansion, such as the takeover bid for Larvotto, were unsuccessful.
In the immediate term, the execution of its $245 million contract with the Defense Logistics Agency remains a central focus. This agreement provides US Antimony with a fundamental runway: the Korea Zinc project is slated for a phased commercial start beginning in 2029, offering several years to stabilize earnings. However, the DoD’s direct involvement in the competing venture undermines the narrative that US Antimony is the primary government-backed domestic solution.
Should investors sell immediately? Or is it worth buying US Antimony?
Market Reaction to a New Competitor
A sharp sell-off in the company’s shares was triggered by the announcement of Korea Zinc’s $7.4 billion refinery project in Clarksville, Tennessee. The facility is planned to produce antimony alongside zinc, copper, and lead. The crucial element is the project’s direct backing with U.S. government funds, via the DoD’s 40% holding in the joint venture. This means US Antimony no longer stands as the sole domestic alternative, and that state-supported competition is likely to influence long-term market share and pricing dynamics.
Investors moved quickly to reduce positions following the news. The equity has declined substantially from its October peak and is now testing key technical levels viewed as sentiment indicators. The nearby support zone around $4.90–$5.00 is particularly relevant, with the current price of $4.92 hovering near the 200-day moving average of $4.82. A sustained break below this level could trigger additional selling pressure.
Strategic Outlook and Key Challenges
The near-term stability of the stock will be dictated by the market’s reaction to its fundamental metrics and the progress on the DLA contract. Looking toward the medium term (until 2029), the company’s competitiveness hinges on its ability to improve profitability and strengthen its balance sheet before the larger, state-supported facility begins operations. The clock is now ticking for US Antimony to solidify its standing.
Ad
US Antimony Stock: Buy or Sell?! New US Antimony Analysis from December 17 delivers the answer:
The latest US Antimony figures speak for themselves: Urgent action needed for US Antimony investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from December 17.
US Antimony: Buy or sell? Read more here...
